These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

691 related articles for article (PubMed ID: 25336717)

  • 1. Circulating tumor cell enumeration with a combination of epithelial cell adhesion molecule- and cell-surface vimentin-based methods for monitoring breast cancer therapeutic response.
    Satelli A; Brownlee Z; Mitra A; Meng QH; Li S
    Clin Chem; 2015 Jan; 61(1):259-66. PubMed ID: 25336717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition.
    Gorges TM; Tinhofer I; Drosch M; Röse L; Zollner TM; Krahn T; von Ahsen O
    BMC Cancer; 2012 May; 12():178. PubMed ID: 22591372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EMT circulating tumor cells detected by cell-surface vimentin are associated with prostate cancer progression.
    Satelli A; Batth I; Brownlee Z; Mitra A; Zhou S; Noh H; Rojas CR; Li H; Meng QH; Li S
    Oncotarget; 2017 Jul; 8(30):49329-49337. PubMed ID: 28521303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EpCAM-Independent Enrichment of Circulating Tumor Cells in Metastatic Breast Cancer.
    Schneck H; Gierke B; Uppenkamp F; Behrens B; Niederacher D; Stoecklein NH; Templin MF; Pawlak M; Fehm T; Neubauer H;
    PLoS One; 2015; 10(12):e0144535. PubMed ID: 26695635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream® in patients with breast cancer treated with primary systemic therapy.
    Le Du F; Fujii T; Kida K; Davis DW; Park M; Liu DD; Wu W; Chavez-MacGregor M; Barcenas CH; Valero V; Tripathy D; Reuben JM; Ueno NT
    PLoS One; 2020; 15(3):e0229903. PubMed ID: 32214335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy.
    Onstenk W; Kraan J; Mostert B; Timmermans MM; Charehbili A; Smit VT; Kroep JR; Nortier JW; van de Ven S; Heijns JB; Kessels LW; van Laarhoven HW; Bos MM; van de Velde CJ; Gratama JW; Sieuwerts AM; Martens JW; Foekens JA; Sleijfer S
    Mol Cancer Ther; 2015 Mar; 14(3):821-7. PubMed ID: 25552367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
    Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
    Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytometric characterization of circulating tumor cells captured by microfiltration and their correlation to the CellSearch(®) CTC test.
    Adams DL; Stefansson S; Haudenschild C; Martin SS; Charpentier M; Chumsri S; Cristofanilli M; Tang CM; Alpaugh RK
    Cytometry A; 2015 Feb; 87(2):137-44. PubMed ID: 25515318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients.
    Lustberg MB; Balasubramanian P; Miller B; Garcia-Villa A; Deighan C; Wu Y; Carothers S; Berger M; Ramaswamy B; Macrae ER; Wesolowski R; Layman RM; Mrozek E; Pan X; Summers TA; Shapiro CL; Chalmers JJ
    Breast Cancer Res; 2014 Mar; 16(2):R23. PubMed ID: 24602188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization and Evaluation of a Novel Size Based Circulating Tumor Cell Isolation System.
    Xu L; Mao X; Imrali A; Syed F; Mutsvangwa K; Berney D; Cathcart P; Hines J; Shamash J; Lu YJ
    PLoS One; 2015; 10(9):e0138032. PubMed ID: 26397728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of circulating tumour cell and the epithelial mesenchymal transition (EMT) status during eribulin-based treatment in 22 patients with metastatic breast cancer: a pilot study.
    Horimoto Y; Tokuda E; Murakami F; Uomori T; Himuro T; Nakai K; Orihata G; Iijima K; Togo S; Shimizu H; Saito M
    J Transl Med; 2018 Oct; 16(1):287. PubMed ID: 30342534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring new frontiers: cell surface vimentin as an emerging marker for circulating tumor cells and a promising therapeutic target in advanced gastric Cancer.
    Li H; Zhu YZ; Xu L; Han T; Luan J; Li X; Liu Y; Wang Z; Liu Q; Kong X; Zou C; Su L; Hou Y; Chen X; Chen L; Wang R; Xu Z; Zhao M
    J Exp Clin Cancer Res; 2024 Apr; 43(1):129. PubMed ID: 38685125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients.
    Kallergi G; Papadaki MA; Politaki E; Mavroudis D; Georgoulias V; Agelaki S
    Breast Cancer Res; 2011 Jun; 13(3):R59. PubMed ID: 21663619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating tumor cell enumeration by the CellSearch system: the clinician's guide to breast cancer treatment?
    Beije N; Jager A; Sleijfer S
    Cancer Treat Rev; 2015 Feb; 41(2):144-50. PubMed ID: 25542852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients.
    Königsberg R; Obermayr E; Bises G; Pfeiler G; Gneist M; Wrba F; de Santis M; Zeillinger R; Hudec M; Dittrich C
    Acta Oncol; 2011 Jun; 50(5):700-10. PubMed ID: 21261508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoroughened adhesion-based capture of circulating tumor cells with heterogeneous expression and metastatic characteristics.
    Chen W; Allen SG; Reka AK; Qian W; Han S; Zhao J; Bao L; Keshamouni VG; Merajver SD; Fu J
    BMC Cancer; 2016 Aug; 16():614. PubMed ID: 27501846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular detection of epithelial-mesenchymal transition markers in circulating tumor cells from pancreatic cancer patients: Potential role in clinical practice.
    Zhao XH; Wang ZR; Chen CL; Di L; Bi ZF; Li ZH; Liu YM
    World J Gastroenterol; 2019 Jan; 25(1):138-150. PubMed ID: 30643364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of aspirin on circulating tumor cells in metastatic colorectal and breast cancer patients: a phase II trial study.
    Yang L; Lv Z; Xia W; Zhang W; Xin Y; Yuan H; Chen Y; Hu X; Lv Y; Xu Q; Weng X; Ni C
    Clin Transl Oncol; 2018 Jul; 20(7):912-921. PubMed ID: 29243075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Size-based isolation of circulating tumor cells in lung cancer patients using a microcavity array system.
    Hosokawa M; Kenmotsu H; Koh Y; Yoshino T; Yoshikawa T; Naito T; Takahashi T; Murakami H; Nakamura Y; Tsuya A; Shukuya T; Ono A; Akamatsu H; Watanabe R; Ono S; Mori K; Kanbara H; Yamaguchi K; Tanaka T; Matsunaga T; Yamamoto N
    PLoS One; 2013; 8(6):e67466. PubMed ID: 23840710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients.
    Huebner H; Fasching PA; Gumbrecht W; Jud S; Rauh C; Matzas M; Paulicka P; Friedrich K; Lux MP; Volz B; Gass P; Häberle L; Meier-Stiegen F; Hartkopf A; Neubauer H; Almstedt K; Beckmann MW; Fehm TN; Ruebner M
    BMC Cancer; 2018 Feb; 18(1):204. PubMed ID: 29463222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.